Parvovirus B19 Infection Associated with Hemolytic Anemia and Cranial Polyneuropathy
| Autor: | Ana Calado, Manuel Manita, Margarida Dias, João Sequeira |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Hemolytic anemia medicine.medical_specialty Anemia Hemolytic Neurology Myelitis Erythema Infectiosum Autoantigens 03 medical and health sciences Cellular and Molecular Neuroscience Polyneuropathies Young Adult 0302 clinical medicine CHLC NEU Virology Gangliosides Optic Nerve Diseases medicine Oculomotor Nerve Diseases Humans Autoantibodies biology Parvovirus business.industry Autoantibody biology.organism_classification medicine.disease 030104 developmental biology Immunology Female Neurology (clinical) business Meningitis Polyneuropathy 030217 neurology & neurosurgery Encephalitis |
| Zdroj: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação instacron:RCAAP |
| Popis: | Parvovirus B19 (PB19) is a common, widespread, small, single-stranded DNA virus which has been linked with a broad spectrum of clinical illnesses, including a variety of neurological complications such as encephalitis, meningitis, myelitis, stroke, cerebellar ataxia, and neuropathy. The authors describe a case of PB19 infection associated with hemolytic anemia and cranial polyneuropathy involving the second and third cranial nerves in a 23-year-old immunocompetent woman. The diagnosis of acute PB19 infection was established with detection of positive DNA and anti-PB19 IgM antibodies in blood samples. Antiganglioside antibody studies were performed and serum anti-GD1b IgG was strongly positive. Further investigation was normal or negative, excluding other infectious or autoimmune disorders. The patient was initially treated with a 5-day course of intravenous immunoglobulin (IGIV). Because of incomplete neurological recovery, methylprednisolone was also administered 7 days after IGIV therapy initiation. Complete resolution of clinical symptoms was observed 3 months after disease onset at follow-up visit, despite the persistence of PB19 DNA and anti-PB19 IgM antibodies in serum 5 months after the initial presentation. Our report provides evidence that PB19 could affect both the central and peripheral nervous system, possibly by triggering an autoimmune mechanism that leads to autoantibody production. info:eu-repo/semantics/publishedVersion |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|